133 related articles for article (PubMed ID: 35444013)
1. ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation.
Garcia-Duran C; Grau F; Villacampa G; Oaknin A
Int J Gynecol Cancer; 2022 Apr; ():. PubMed ID: 35444013
[TBL] [Abstract][Full Text] [Related]
2. CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study.
Mayadev J; Nunes AT; Li M; Marcovitz M; Lanasa MC; Monk BJ
Int J Gynecol Cancer; 2020 Jul; 30(7):1065-1070. PubMed ID: 32447296
[TBL] [Abstract][Full Text] [Related]
3. PARa-aOrtic LymphAdenectomy in locally advanced cervical cancer (PAROLA trial): a GINECO, ENGOT, and GCIG study.
Martinez A; Lecuru F; Bizzarri N; Chargari C; Ducassou A; Fagotti A; Fanfani F; Scambia G; Cibula D; Díaz-Feijoo B; Gil Moreno A; Angeles MA; Muallem MZ; Kohler C; Luyckx M; Kridelka F; Rychlik A; Gerestein KG; Heinzelmann V; Ramirez PT; Frumovitz M; Ferron G; Betrian S; Filleron T; Fotopoulou C; Querleu D;
Int J Gynecol Cancer; 2023 Feb; 33(2):293-298. PubMed ID: 36717163
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
Grau JF; Farinas-Madrid L; Oaknin A
Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
[TBL] [Abstract][Full Text] [Related]
5. Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB-IVA: oncologic results of a prospective randomized international multicenter (Uterus-11) intergroup study.
Marnitz S; Tsunoda AT; Martus P; Vieira M; Affonso Junior RJ; Nunes J; Budach V; Hertel H; Mustea A; Sehouli J; Scharf JP; Ulrich U; Ebert A; Piwonski I; Kohler C
Int J Gynecol Cancer; 2020 Dec; 30(12):1855-1861. PubMed ID: 33293284
[TBL] [Abstract][Full Text] [Related]
6. Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer.
Mayadev J; Zamarin D; Deng W; Lankes H; O'Cearbhaill R; Aghajanian CA; Schilder R
Int J Gynecol Cancer; 2020 May; 30(5):701-704. PubMed ID: 31871115
[TBL] [Abstract][Full Text] [Related]
7. A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial.
Gonzalez Martin A; Sanchez Lorenzo L; Colombo N; dePont Christensen R; Heitz F; Meirovitz M; Selle F; van Gorp T; Alvarez N; Sanchez J; Marqués C
Int J Gynecol Cancer; 2021 Apr; 31(4):617-622. PubMed ID: 33318079
[TBL] [Abstract][Full Text] [Related]
8. Primary chemoradiation versus neoadjuvant chemotherapy followed by surgery as treatment strategy for locally advanced vulvar carcinoma (VULCANize2).
Amant F; van Velzen AF; Reyners A; Zijlmans H; Schaake EE; Nooij L
Int J Gynecol Cancer; 2024 May; ():. PubMed ID: 38719277
[TBL] [Abstract][Full Text] [Related]
9. Robot-assisted approach to cervical cancer (RACC): an international multi-center, open-label randomized controlled trial.
Falconer H; Palsdottir K; Stalberg K; Dahm-Kähler P; Ottander U; Lundin ES; Wijk L; Kimmig R; Jensen PT; Zahl Eriksson AG; Mäenpää J; Persson J; Salehi S
Int J Gynecol Cancer; 2019 Jul; 29(6):1072-1076. PubMed ID: 31203203
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer.
Tangjitgamol S; Katanyoo K; Laopaiboon M; Lumbiganon P; Manusirivithaya S; Supawattanabodee B
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010401. PubMed ID: 25470408
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of PD-1 inhibitor combined with concurrent chemoradiotherapy in locally advanced cervical cancer with pelvic and/or para-aortic lymph node metastases: a retrospective cohort study.
Liu C; Ran X; Wang Z; Zhang K
Chin Clin Oncol; 2023 Aug; 12(4):38. PubMed ID: 37699603
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial.
Shrivastava S; Mahantshetty U; Engineer R; Chopra S; Hawaldar R; Hande V; Kerkar RA; Maheshwari A; Shylasree TS; Ghosh J; Bajpai J; Gurram L; Gulia S; Gupta S;
JAMA Oncol; 2018 Apr; 4(4):506-513. PubMed ID: 29423520
[TBL] [Abstract][Full Text] [Related]
13. The upper limit of optimal tumor size in patients with FIGO 2018 stage IB2 cervical cancer undergoing radical hysterectomy.
Hwang WY; Kim JH; Suh DH; Kim K; No JH; Kim YB
Int J Gynecol Cancer; 2020 Jul; 30(7):975-980. PubMed ID: 32467336
[TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
15. Perioperative morbidity and rate of upstaging after laparoscopic staging for patients with locally advanced cervical cancer: results of a prospective randomized trial.
Köhler C; Mustea A; Marnitz S; Schneider A; Chiantera V; Ulrich U; Scharf JP; Martus P; Vieira MA; Tsunoda A
Am J Obstet Gynecol; 2015 Oct; 213(4):503.e1-7. PubMed ID: 25986030
[TBL] [Abstract][Full Text] [Related]
16. Pre-treatment surgical para-aortic lymph node assessment in locally advanced cervical cancer.
Brockbank E; Kokka F; Bryant A; Pomel C; Reynolds K
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008217. PubMed ID: 23543561
[TBL] [Abstract][Full Text] [Related]
17. Oncologic outcome after completing or abandoning (radical) hysterectomy in patients with cervical cancer and intraoperative detection of lymph node positivity; ABRAX (ABandoning RAd hyst in cerviX cancer).
Dostalek L; Runnebaum I; Raspagliesi F; Vergote I; Dusek L; Jarkovsky J; Cibula D
Int J Gynecol Cancer; 2020 Feb; 30(2):261-264. PubMed ID: 31748245
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
19. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
20. Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence; AGO-OP.6).
Emons G; Kim JW; Weide K; de Gregorio N; Wimberger P; Trillsch F; Gabriel B; Denschlag D; Kommoss S; Aydogdu M; Papathemelis T; Gropp-Meier M; Muallem MZ; Kühn C; Müller A; Frank M; Weigel M; Bronger H; Lampe B; Rau J; Schade-Brittinger C; Harter P
Int J Gynecol Cancer; 2021 Jul; 31(7):1075-1079. PubMed ID: 34226291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
